| Ovarian Serous Tumor studied in …STUDIED_INderived160 of 160show fewer |
|---|
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03564340Phase 1/Phase 2 · recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832227Phase 2 · not yet recruiting Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07821879recruiting Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772869NA · recruiting Uterine Lavage to Detect Ovarian Cancer Risk · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04633239Phase 1 · recruiting Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595892Phase 2 · active not recruiting Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585958Phase 1 · recruiting Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02208375Phase 1 · active not recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791732Phase 3 · not yet recruiting A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281471Phase 3 · recruiting Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554367Phase 2 · active not recruiting Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03096054Phase 1 · completed A Phase I Trial of LY3143921 Hydrate in Solid Tumours · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415709early Phase 1 · active not recruiting Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06072781Phase 3 · recruiting A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03943173early Phase 1 · active not recruiting Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00488878recruiting Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05114421Phase 2 · active not recruiting Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06188520Phase 1/Phase 2 · recruiting A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07747506Phase 2 · not yet recruiting Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101788Phase 2/Phase 3 · completed Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Borderline Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05579366Phase 1/Phase 2 · recruiting Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627443Phase 1 · active not recruiting Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03586661Phase 1 · completed Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06394804Phase 2 · recruiting A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116648Phase 1/Phase 2 · active not recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05057715Phase 1 · active not recruiting huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451849Phase 1/Phase 2 · terminated A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587311Phase 2 · active not recruiting Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01883297Phase 1 · active not recruiting "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05005403Phase 1 · recruiting Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07503808Phase 1 · recruiting A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06494150Phase 2 · active not recruiting Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00951496Phase 3 · completed Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039801Phase 1 · recruiting IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01167712Phase 3 · active not recruiting Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04314401active not recruiting National Cancer Institute "Cancer Moonshot Biobank" · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05027828recruiting CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02659241early Phase 1 · active not recruiting Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06451497Phase 1 · recruiting This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04498117Phase 3 · active not recruiting Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05605535Phase 2 · active not recruiting Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04095364Phase 3 · active not recruiting Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05500391Phase 2 · recruiting Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03875820Phase 1 · active not recruiting Phase I Trial of Defactinib and VS-6766. · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07432594Phase 2 · not yet recruiting Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00565851Phase 3 · active not recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06682572Phase 2 · active not recruiting A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07269574not yet recruiting Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07268469NA · not yet recruiting Minimal Residual Disease in Solid Malignancies · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05512208Phase 2 · recruiting A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05329532Phase 1/Phase 2 · recruiting Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04794322recruiting Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05998135Phase 2 · recruiting Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907852Phase 1/Phase 2 · active not recruiting Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05113368Phase 2 · recruiting Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06976892Phase 1 · recruiting Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04159155Phase 2/Phase 3 · terminated A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04458597NA · completed Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07068178Phase 2 · not yet recruiting Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02713386Phase 1/Phase 2 · completed Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02756130Phase 1/Phase 2 · withdrawn Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03456700Phase 2 · terminated Auranofin and Sirolimus in Treating Participants With Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02569957Phase 2 · terminated Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Malignant Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03610490Phase 2 · terminated Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03268382Phase 2 · completed p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084195NA · recruiting Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04625270Phase 2 · active not recruiting A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06787170completed Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04846933NA · recruiting Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06777082recruiting Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06553742not yet recruiting High Definition Profiling of Ovarian Cancer Ascites · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02953457Phase 2 · completed Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03648489Phase 2 · completed Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05001282Phase 1/Phase 2 · terminated A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05538624Phase 1/Phase 2 · terminated A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02923739Phase 2 · terminated Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05074472Phase 1/Phase 2 · completed A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606486NA · terminated Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04716686Phase 2 · recruiting Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641287NA · terminated The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05961124Phase 2 · recruiting Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849874Phase 3 · terminated A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05329545Phase 3 · terminated Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05295589Phase 2 · withdrawn Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06055348Phase 1/Phase 2 · unknown SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02898207Phase 1 · completed Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03507452Phase 1 · completed First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin · condition mapped CURATED_BROADER · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05062174withdrawn Breast Cancer BRCA1 Carriers: a Pilot Study · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01097746Phase 2 · completed First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03123211no longer available Expanded Access to Veliparib · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03924245Phase 1 · terminated Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02316834early Phase 1 · completed Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ALIAS · 160 trials mapped (80 active) | — | — | Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05188781completed Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05146505unknown miRNAs in High Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00888615Phase 2 · completed Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00989651Phase 1 · completed Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02853318Phase 2 · completed Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00108745Phase 3 · unknown Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03685695Phase 2 · completed Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00551070Phase 2 · completed Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Borderline Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02283658Phase 2 · completed Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04261465Phase 2 · unknown NUVOLA TRIAL Open-label Multicentre Study · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02307240Phase 1 · completed Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01504126early Phase 1 · completed Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520115Phase 1 · completed Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01074411Phase 1 · completed Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00262847Phase 3 · completed Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00993616Phase 2 · completed Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02179970Phase 1 · completed To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00079430Phase 1 · completed Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00085358Phase 1 · completed Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01459380Phase 1 · completed Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00357448Phase 1 · completed Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01489371Phase 1 · completed EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02050009Phase 1 · withdrawn Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00939809Phase 2 · completed A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00899093terminated YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Malignant Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01275664NA · terminated Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01080521completed Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00719303Phase 3 · unknown Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01853306Phase 1 · completed A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00466960Phase 2 · completed Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00004221Phase 2 · terminated Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00897442completed Collecting Tumor Samples From Patients With Gynecological Tumors · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Borderline Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627430Phase 1 · withdrawn Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02470559Phase 1 · withdrawn Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Malignant Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00059787Phase 2 · completed Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00053235withdrawn Research Study in Patients With Advanced Ovarian Epithelial Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060359Phase 1 · completed Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02016833completed Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00814086Phase 1 · completed Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01492920Phase 3 · withdrawn Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01294293Phase 1 · completed TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00002913Phase 1 · completed Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 160 trials mapped (80 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |